JNJ-38877605是一种ATP竞争性的c-Met抑制剂,IC50为4 nM,作用于c-Met比作用于200种其他酪氨酸和丝-苏氨酸激酶选择性高600倍。
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. Phase 1.
≤40 mg/kg/day口服处理
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Perera T, et al. Presented at the 99th AACR Annual Meeting; 2008 Apr 12-16; San Diego (CA): Abst
[2] Martijn P. Lolkema,et al. The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species specific insoluble metabolite formation. Clin Cancer Res. Author manuscript; available in PMC 2015 Nov 15. Published in final edited form as: Clin Cancer Res. 2015 May 15; 21(10): 2297–2304. Published online 2015 Mar 5. doi: 10.1158/1078-0432.CCR-14-3258.
[3] Wenzhi Li,et al. Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. Int J Clin Exp Med. 2015; 8(4): 6563–6567. Published online 2015 Apr 15..
分子式 C19H13F2N7 |
分子量 377.35 |
CAS号 943540-75-8 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 37 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT00651365 | Neoplasms | Drug: JNJ-38877605 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho Biotech, Inc. | Phase 1 | 2008-02-01 | 2013-03-07 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们